Can’t you turn on Developer Mode to enable third party slicers?

I think of the Bambu P1S as the inexpensive alternative to the Bambu X1C or a comparable printer from Prusa, at least in terms of print consistency and ease of use.

My Bambu was my fourth 3D printer (second FDM printer) and it took 3D printing from a frustrating, time consuming hobby to just a thing I do to enable other hobbies. I don’t have to spend time tweaking settings to get a decent print, because the default settings are already good enough. Instead, I can focus on designing models or working with finished prints.

I’ll have to check out both OpenSCAD and Code Comic. Some completely non-CAD DSLs that you might be interested in, since you mentioned GraphViz:

Mermaid.js does something very similar to Graphviz. There are a couple other similar tools like that out there, but Mermaid is supported in a lot of places natively or as an easy to use plugin, like GitHub Markdown (and other git forges like Forgejo), Hedgedoc, Obsidian, SilverBullet, etc…

I’d also argue that LaTeX counts, and to a lesser extent, Markdown - compare using them to using Word.

And reveal.js is an equivalent for slide deck creation that would normally be done with PowerPoint.

What have you done to clean the bed? From the link to the textured sheet, you should be cleaning it between every print - after it cools - with 90% IPA, and if you still have adhesion issues, you should clean it with warm water and a couple drops of dish soap.

Has the TPU been dried? I don’t normally print with TPU but my understanding is that it needs to be lower humidity than PLA; I use dryboxes for PLA and target a humidity of 15% or lower and don’t use them if they raise above 20%. The recommendation I saw for TPU was to dry it for 7 hours at 70 degrees Celsius, to target 10% humidity (or at least under 20%) and to print directly from a drybox. Note that compared to other filaments, TPU can’t recover as well from having absorbed moisture - if the filament has gotten too wet, it’ll become too brittle if you dry it out as much as is needed. At that point you would need to start with a fresh roll, which would ideally go into a dryer and then drybox immediately.

You should be able to set different settings for the initial layer to avoid stringing, i.e., slower speeds and longer retraction distance. It’s a bit more complicated but you can also configure the speed for a specific range of layers to be slower - i.e., setting it to slow down again once you get to the top of the print. For an example of that, see https://forum.prusa3d.com/forum/prusaslicer/bed-flinger-slower-y-movement-as-function-of-z/

What’s the max speed you’re printing at? My understanding is that everything other than travel should all be the same speed at a given layer, and no higher than 25 mm/s. And with a bed slinger I wouldn’t recommend a much higher travel, either.

In addition to a brim, have you tried adding supports?

Your reply has nothing to do with fair use doctrine.

Copyright can only be granted to works created by a human, but I don’t know of any such restriction for fair use. Care to share a source explaining why you think only humans are able to use fair use as a defense for copyright infringement?

And acting like they were the only people responsible diminishes the achievements of everyone involved since.

We don’t use that insulin today. Why do you think we do?

It’s a shame that the people involved with this lawsuit are either ignorant or intentionally misleading their audience.

And over the last 20 years, we have seen over a 1000% increase in spite of the fact nothing’s changed with the drug. The cost to produce it has gotten lower. But we are getting screwed hundreds, possibly thousands of dollars a month.

“Insulin” is more than just one drug. Traditional (short lasting) insulin is relatively cheap. A “Novolin N or R ReliOn vial” (which I just learned is available over the counter) with 1000 units of insulin is $25. Rapid and long lasting insulins are what’s expensive, but those are recent advancements. See https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864088/ for a list of some of these.

It’s weird that he says prices have gone up 1000% over the last 20 years. According to https://www.goodrx.com/healthcare-access/research/how-much-does-insulin-cost-compare-brands prices went up 54% from 2014 to 2019 and dropped 10% from 2020 to 2023. Is he really suggesting that prices went up 590% from 2003 to 2013? I wasn’t able to verify that claim. According to https://www.reuters.com/article/idUSKCN0X22B0/ the price went up 197% from 2002 to 2013. Added up that means prices have gone up 310% in the past 21 years. That’s still a lot but also: inflation since then is 73%. Account for inflation and that 310% increase drops to a 140% increase - a 7th of the alleged 1000% increase. That’s basically how much housing prices have gone up in that same time period. That’s still a lot and it’s still shitty, but if you have to make up numbers to get your point across, I question whether you’re the best person to be conveying that point.

According to https://diabetes.org/tools-resources/affordable-insulin both Sanofi and Lilly have programs that cap out of pocket expenses for most people to $35 a month, and that includes the new drugs. If someone you know is struggling to pay for their insulin, make sure they know about these programs. They’re getting a lot more marketing now that the federal government negotiated the $35 cap for medicaid/medicare patients, but those programs have been around for a while. It’s frustrating to see so many discussions about how pharmaceutical companies are exploiting people without anyone sharing (or even mentioning) the resources that can help them.

It’s also frustrating that all of the claims about companies colluding are completely unbacked. Is there any evidence of this? I don’t find it hard to believe that pharmaceutical companies price their products as high as they can because they like money. I certainly don’t trust a person who’s already shown his other statements to be demonstrably untrue when he makes a statement that can’t be verified one way or another.

The anti-R&D arguments are also exhausting. Pharmaceutical companies do spend a ton of money on R&D - according to https://www.investopedia.com/ask/answers/060115/how-much-drug-companys-spending-allocated-research-and-development-average.asp Lilly spent a quarter of their revenue on R&D in 2020 (I didn’t see the other names mentioned). No, that’s no 80+% like it’s made out to be, but it does mean that the most prices could possibly be reduced without negatively impacting innovation is to a quarter of where they were in 2020, and that’s assuming that someone else pays for all the other expenses (manufacturing, distribution, marketing, education, etc.). According to that article, “The average R&D to marketplace cost for a new medicine is nearly $4 billion, and can sometimes exceed $10 billion.” According to https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855407/ the top end of that range is more like $6 billion, but still. Either way, that money has to come from somewhere.

It’s good to see PBMs mentioned, though. They’re literally middlemen who provide 0 value. Even if they’re not doing anything illegal they should still be outlawed.